Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease

Manuela Dicarlo,Patrizia Pignataro,Chiara Zecca,Maria Teresa Dell'Abate,Daniele Urso,Valentina Gnoni,Alessia Giugno,Francesco Borlizzi,Roberta Zerlotin,Angela Oranger,Graziana Colaianni,Silvia Colucci,Giancarlo Logroscino,Maria Grano
DOI: https://doi.org/10.1002/ana.26946
IF: 11.2
2024-05-25
Annals of Neurology
Abstract:Objective Irisin, released by muscles during exercise, was recently identified as a neuroprotective factor in mouse models of Alzheimer disease (AD). In a cohort of AD patients, we studied cerebrospinal fluid (CSF) and plasma irisin levels, sex interactions, and correlations with disease biomarkers. Methods Correlations between CSF and plasma irisin levels and AD biomarkers (amyloid β 1‐42, hyperphosphorylated tau, and total tau [t‐tau]) and Clinical Dementia Rating Scale Sum of Boxes (CDR‐SOB) were analyzed in a cohort of patients with Alzheimer dementia (n = 82), mild cognitive impairment (n = 44), and subjective memory complaint (n = 20) biologically characterized according to the recent amyloid/tau/neurodegeneration classification. Results CSF irisin was reduced in Alzheimer dementia patients (p
neurosciences,clinical neurology
What problem does this paper attempt to address?